Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

Chronic Kidney Disease Clinical Trial

Official title:

Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01012089
• Other study ID #: 2375
• Status: Completed
• Phase: N/A
• Start date: November 2009
• Est. completion date: April 2014

Study information

• Verified date: May 2018
• Source: University of Oklahoma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to:

1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD).

2. Determine urine, HD and PD clearance of daptomycin.

Description:

Infectious and sepsis events are one of the most common complications in children with chronic kidney disease. The incidence is highest in children with an access for dialysis, especially in those with catheters. Staphylococcal species account for more than 50% of access infections (ranging from 58-77%). Failure to clear the infection results in loss of dialysis access.

Daptomycin is a new antibiotic that provides coverage against most gram positive bacteria including methicillin-resistant staphylococci, vancomycin-intermediate Staphylococcus aureus, and vancomycin-resistant enterococci. The pharmacokinetics of daptomycin in children on dialysis, a group of patients who may need the medication the most, remains unknown.

Children on HD or PD with suspected or confirmed infections due to gram-positive bacteria and who are concurrently treated with standard of care antibiotics will be considered for this study. Each patient will be given a onetime dose of Cubicin (daptomycin). After receiving daptomycin, serial blood samples along with dialysis effluent and urine (obtained from non-anuric patients) will be collected to evaluate the pharmacokinetic profile of the drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

• Children who are between 12-17 years of age who are either on HD or PD and whom the Pediatric Nephrology Section of the OU Children's Physicians Clinics provide care.

• In addition to children on chronic HD and PD therapy, patients newly initiated on HD and PD will also be recruited for this study.

• Patients with suspected or confirmed cases of dialysis related infection from gram-positive bacteria and who are receiving standard of care antibiotics.

• Patients will be eligible for enrollment if they were admitted as an inpatient to the Children's hospital or as an outpatient to the dialysis clinic

Exclusion Criteria:

• Patients > 17 years of age

• Patients < 12 years of age

• Total amount of blood drawn as part of standard of care and for pharmacokinetic analysis exceeds 3 ml/kg over an 8 week period

• Taking an HMG CoA reductase inhibitor within 7 days of daptomycin administration

• Having used daptomycin in the 30 days preceding study entry

• Participating in any experimental procedure in the 30 days preceding study

• A history of muscular disease or neurological disease

• Baseline creatine phosphokinase (CPK) values equal to or greater than 1.5 times the upper limit of normal (normal range 65-370 IU/L)

• Hemoglobin < 9 g/dl

• Hemodynamic instability within 72 hours before study enrollment

• Female subjects with a positive pregnancy test or failure to take a pregnancy test

Related Conditions & MeSH terms

• Bacterial Infection
• Bacterial Infections
• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Daptomycin
Daptomycin IV 5 mg/kg one time dose

Locations

Country	Name	City	State
United States	The Children's Hospital at the University of Oklahoma Medical Center	Oklahoma City	Oklahoma

Sponsors (2)

Lead Sponsor	Collaborator
University of Oklahoma	Cubist Pharmaceuticals LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Plasma Concentration (Cmax)		0, 0.5, 2, 3, 4.5 6, 24, and 48 hours post dose
Primary	Area Under the Concentration Time Curve From Time Zero to 24 Hours (AUC0-24)		0, 0.5, 2, 3, 4.5, 6, and 24 hours post dose
Primary	Area Under the Concentration Time Curve From Time Zero to 48 Hours (AUC0-48)		0, 0.5, 2, 3, 4.5 6, 24, and 48 hours post dose
Primary	Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-8)		0, 0.5, 2, 3, 4.5, 6, 24, and 48 hours post dose
Primary	Volume of Distribution at Steady State (Vss)	The theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug	0, 0.5, 2, 3, 4.5, 6, 24, and 48 hours post dose
Primary	Elimination Rate Constant (Ke)		0, 0.5, 2, 3, 4.5, 6, 24, and 48 hours post dose
Primary	Total Drug Clearance (CLtotal)	The rate at which a drug substance is removed from the body	0, 0.5, 2, 3, 4.5, 6, 24, and 48 hours post dose
Primary	Drug Clearance Due to Dialysis (CLdialysis)	The rate at which a drug substance is removed from the body due to dialysis therapy	0, 0.5, 2, 3, 4.5, 6, 24, and 48 hours post dose